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SCA2 presenting as an ataxia-parkinsonism-motor  
neuron disease syndrome
Pedro Braga-Neto, José Luiz Pedroso, André Carvalho Felício, Agessandro Abrahão,  
Lívia Almeida Dutra, Marcio Luiz Escorcio Bezerra, Orlando Graziani Povoas Barsottini
The procedures followed were in accordance with the 
ethical standards of the responsible committee on human 
experimentation (institutional and national). All subjects 
were provided with the approved informed consent. 
Spinocerebellar ataxia type 2 (SCA2) is characterized 
by progressive cerebellar ataxia, slow saccadic eye move-
ments and peripheral neuropathy. Atypical SCA2 pheno-
types with prominent dementia, an amyotrophic lateral 
sclerosis-like presentation, and levodopa-responsive par-
kinsonism are also encountered1. The definite diagnosis 
of SCA2 is based on clinical symptoms and molecular ge-
netic testing to detect an abnormal CAG trinucleotide 
repeat expansion of the ATXN2 gene on chromosome 
12q1. The protein synthesized by ATXN2 is known as 
ataxin-2 that is involved in RNA metabolism and trans-
lation regulation1. Herein we report an unusual case 
of SCA2 presenting as an ataxia-parkinsonism-motor 
neuron disease (MND) syndrome.
CASE 
A 46-year-old Brazilian man of Italian ancestry, pre-
sented for consultation because of progressive gait insta-
bility and muscle cramps that started 18 months before. 
He also developed rapidly progressive muscle weakness 
few months before his first appointment. His family his-
tory revealed affected individuals (ataxia) within first and 
second generations. On neurological examination, there 
were mild dysarthria, slow saccades, mild limb and gait 
ataxia, parkinsonism, brisk reflexes and bilateral Babinski 
sign. He also presented muscle weakness in upper limbs, 
diffuse fasciculations and atrophy involving upper limbs, 
chest and face. Genetic testing confirmed the diagnosis 
of SCA2 with 40 CAG repeats. Brain magnetic reso-
nance imaging (MRI) disclosed cerebellar and brain-
stem atrophy (Figure). Electroneuromyography showed 
denervation activity at rest, with fasciculation, fibrillation 
and positive sharp wave potentials in the bulbar, cervical, 
thoracic and lumbosacral regions. Nerve conduction 
studies showed normal sensory and motor nerve con-
duction velocities and reduced amplitudes of the motor 
potentials. We introduced riluzole 50 mg b.i.d. as treat-
ment for amyotrophic lateral sclerosis (ALS). 
DISCUSSION
Few previous studies have described the association 
of SCA2 with MND. Infante et al.2 reported a case of a 61 
years-old woman with SCA2 diagnosis who developed a 
levodopa-responsive parkinsonism after 6 months of the 
ataxia-onset of symptoms, but later on disease course 
Figure. Sagittal T1 brain MRI disclosing cerebellar and brainstem 




presented MND syndrome2. Recently, Nanetti et al.3 de-
scribed another 66 year-old woman with SCA2 affected 
with progressive weakness and fasciculation3. Our pa-
tient was younger than the previous reports and pre-
sented MND disease shortly after SCA2 diagnosis.
In 2006, the 43-kDa TAR DNA binding protein 
(TDP-43) was identified as the major disease protein in 
ALS and frontotemporal lobar degeneration with ubiqui-
nated inclusions4. Recently, Elden et al.5 pointed out to 
ATXN2 gene as a relatively common suitability gene to 
ALS. They demonstrated that ATXN2 is a potent modi-
fier of TDP-43 toxicity in animal and cellular models. In 
addition, 6 patients with ALS were evaluated and dis-
closed different ATXN2 localization in spinal cord5. 
This report highlights that unusual phenotypes such 
as an ataxia-parkinsonism-motor neuron disease syn-
drome may be found in SCA 2 individuals. This raises 
several questions such as whether or not patients inves-
tigating MND with or without known family members 
with cerebellar ataxia should be routinely screened for 
ATXN2. Future studies with larger series are welcome to 
address these questions.
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Facial grimacing as a clue for the diagnosis 
of GM1 type 3 gangliosidosis
Ricardo Oliveira Horta Maciel1, José Luiz Pedroso2, Orlando G.P. Barsottini3
GM1 Gangliosidosis is an autosomal recessive lyso-
somal storage disease caused by the deficiency of beta-
galactosidase. Only few cases have been reported in the 
literature, owing to the rarity of the condition but also 
possibly due to its underrecognition in clinical practice1,2. 
Reports of GM1 gangliosidosis type 3 patients and recent 
literature review shows that oromandibular dystonia pro-
ducing the aprearance of grimacing is a common feature 
of this disorder2. Herein we describe a patient in wich 
proeminent facial grimacing served as a clue to the di-
agnosis of GM1 gangliosidosis type 3. The patients legal 
guardian gave consent to publish this case.
A 20 year-old female patient had a normal develop-
ment until the age of 3 years, when the parents noted 
speech impairment wich worsened to the point of in-
inteligibility in the following years. With 5 years cog-
nitive deterioration in other areas was noted and the 
child was never able to attend school. Gait abnormality 
also developed and by the age 11 she was unable to walk 
or stand. On examination the patient had short stature 
and moderate thoracic kyphosis. Tongue and orofacial 
dystonia where present, giving the appearance of gri-
macing (Figure). There was also dystonia of the feet, dys-
tonic posturing of the hands while at rest and increased 
tonus in the legs. No bradykynesia or dysmetria were 
noted. Strenght was normal with brisk reflexes and flexor 
plantar responses. There was no corneal clouding. Slit-
lamp examination and fundoscopy were normal. Bone 
radiographies revealed kyphoscoliosis and femoral dys-
plasia. Routine brain MRI showed T2 hypointensity of 
the globus pallidus and hydrocephalus caused by a in-
cidental ependimoma of the fourth ventricule. Routine 
blood and CSF examination were unremarkable. An ab-
dominal ultrasound showed no abnormalities. Beta-gli-
curonidase, galacto-6-sulphatase and hexosaminidase A 
(testing for mucopolysaccharidosis IV, VII and Tay-Sachs 
disease, respectively) were normal. Leukocyte beta-ga-
lactosidade activity measured in serum was 5.7 nmol/h/
